What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL”In the company’s words, NCT04137562 on ClinicalTrials.gov
- Tested for
- Atopic Dermatitis (2 trials)
- Main trialPhase 3
- “Study of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis”In the company’s words, NCT07377838 on ClinicalTrials.gov
Other drugs for Atopic Dermatitis
Coming up1
- Sep 2029Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 13 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07377838
- 13 NovCompletion date moved: 2029-06 to 2029-09 · ClinicalTrials.gov NCT07377838
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Sep 2029 | Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis | |
| Phase 2Active, not recruiting | 26 Jan 2023 | Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026